SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

Tysabri

RPRX·Royalty Pharma plc
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2004. No further regulatory milestones for the originator product.
Why 3/10
Tysabri is an already-approved, marketed drug with no pending regulatory decision or binary catalyst. For Royalty Pharma, it is one of 35+ royalty assets in a diversified portfolio. The drug faces gradual biosimilar erosion, but this is a commercial headwind, not a binary event. No hard, dated catalyst exists for Tysabri in the next 12 months, so the impact score is capped at 3-5 per the rubric for approved drugs with no pending decision.
Actionable Insight NEUTRAL

Tysabri has no upcoming binary catalysts; it is a mature product in gradual biosimilar-driven decline. For Royalty Pharma, the key question is how quickly Tysabri royalties erode versus growth in the rest of the portfolio. Watch Biogen's quarterly Tysabri sales reports for the pace of market share loss to Tyruko, and monitor Royalty Pharma's portfolio receipts disclosures for the Tysabri royalty trend. Royalty Pharma's next portfolio-wide catalyst is the PDUFA date for neladalkib on November 27, 2026, a separate drug entirely.

Price Chart

Loading chart...

Executive Summary

Tysabri (natalizumab) is a mature, FDA-approved monoclonal antibody for relapsing forms of multiple sclerosis and Crohn's disease, developed and marketed by Biogen Inc. Royalty Pharma plc (RPRX) is not the developer but owns a royalty stream on global Tysabri sales, acquired from Perrigo in 2017 for up to $2.85 billion. The royalty rate is reportedly 18% of annual net global sales up to $2 billion and 25% above that. Tysabri generated $1.665 billion in global sales in 2025 (down 2.9% year-over-year), and faces growing biosimilar competition from Tyruko (Sandoz/Novartis), which launched in Europe in 2023 and the US in November 2025. Royalty Pharma expects Tysabri royalty receipts to decline in 2026. For Royalty Pharma investors, Tysabri is a gradually declining asset within a broadly diversified portfolio of 35+ commercial-stage royalties, where growth from other products is offsetting the Tysabri headwind.

How It Works

Tysabri is a monoclonal antibody that blocks immune cells from crossing into the brain and spinal cord. It works by binding to a protein (alpha-4 integrin) on the surface of inflammatory immune cells, preventing them from attaching to and passing through the blood-brain barrier. This reduces the immune attack on nerve cells in multiple sclerosis and inflammation in Crohn's disease.

Trial Status

Tysabri was initially FDA-approved in November 2004 for relapsing forms of multiple sclerosis. It was temporarily withdrawn from the market in 2005 due to safety concerns (PML risk) but returned in 2006 under a restricted distribution program (TOUCH). It was also approved for moderately to severely active Crohn's disease in 2008. The drug is now a mature, marketed product with over 20 years of real-world use. A biosimilar (Tyruko, by Sandoz/Novartis) was FDA-approved in August 2023 and launched in Europe in 2023 and the US in November 2025.

The Two-Sided Case

▲ Bull Case4
Tysabri remains a significant revenue generator for Biogen with $1.665 billion in global sales in 2025, and Royalty Pharma collects a royalty on those sales (reportedly 18% up to $2 billion and 25% above that threshold).
Royalty Pharma acquired the Tysabri royalty stream in 2017 for up to $2.85 billion, and the drug has continued to generate substantial royalty income for years since, demonstrating the durability of the royalty model.
Tysabri's decline has been gradual (only 2.9% revenue decline in 2025 despite biosimilar competition in Europe), suggesting the brand retains meaningful market share and patient loyalty.
Royalty Pharma's portfolio is highly diversified across 35+ commercial products, so Tysabri's gradual decline is being offset by growth in other assets like Trikafta, Trelegy, and Evrysdi.
▼ Bear Case5
Tysabri faces direct biosimilar competition from Tyruko (Sandoz/Novartis), which launched in Europe in 2023 and the US in November 2025, putting sustained downward pressure on sales and royalties.
Royalty Pharma itself stated in its Q1 2026 pre-quarterly communication that it expects Royalty Receipts from Tysabri to decline in 2026 due to biosimilar competition.
Tysabri carries a boxed warning for progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection, which limits its addressable patient population and creates ongoing safety liability.
Patent protection is eroding: foundational composition patents have lapsed, and remaining use patents extend to 2027-2029, meaning biosimilar competition will likely intensify over time.
For Royalty Pharma specifically, Tysabri is a declining royalty asset in a portfolio where the company's growth is being driven by newer drugs, making it a headwind rather than a growth driver.

Upcoming Catalysts

  • None for Tysabri itself. The drug is a mature marketed product with no pending regulatory decisions. Royalty Pharma's next portfolio catalyst is the PDUFA date for neladalkib (a different drug) on November 27, 2026.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Royalty Pharma plc PRESS-RELEASE RPRX ·Originating report

Sources · 10

Hover a chip for the title
1 en.wikipedia.org2 royaltypharma.com3 fda.gov4 royaltypharma.com5 royaltypharma.com6 eradigm.com7 publicnow.com8 fool.com9 sec.gov10 marketscreener.com